CLIO-8221

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameCLIO-8221
Drug Alias NameCLIO-8221HMBD-802HMBD802CLIO8221
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionDNA topoisomerase I inhibitorsSerine-protein kinase ATR inhibitorsAnti-HER2
TargetsDNA topoisomerase ISerine-protein kinase ATRReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaIND
Originator CompaniesHummingbird Bioscience
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCallio Therapeutics IncShanghai PPC Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A